TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02416388

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ID cytarabine
Description: Consolidation chemotherapy course (s) :~-Intermediate dose cytarabine: 1.5g/m² /12h on D1, D3 and D5~For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)~Up to 3 consolidation courses, depending on the patient AML risk group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ID cytarabine
Description: Consolidation chemotherapy course (s) :~-Intermediate dose cytarabine: 1.5g/m² /12h on D1, D3 and D5~For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)~Up to 3 consolidation courses, depending on the patient AML risk group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID cytarabine
Description: Consolidation chemotherapy course (s) :~-Intermediate dose cytarabine: 1.5g/m² /12h on D1, D3 and D5~For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)~Up to 3 consolidation courses, depending on the patient AML risk group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID cytarabine
Description: Consolidation chemotherapy course (s) :~-Intermediate dose cytarabine: 1.5g/m² /12h on D1, D3 and D5~For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)~Up to 3 consolidation courses, depending on the patient AML risk group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Consolidation chemotherapy course (s) :~-10 mg/12h on D1, D3 and D5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Consolidation chemotherapy course (s) :~Once RP2D has been determined from the results of the dose selection phase (phase 1), the optimal dose level retained for randomized phase 2 will be one of the following:~* 100 mg/d on D1 to D8 (selection phase dose level 1)~* or 200 mg/d on D1 to D8 (selection phase dose level 2)~* or 400 mg/d on D1 to D8 (selection phase dose level 3)~* or 400 mg/d on D1 to D14 (selection phase dose level 4)
Study: NCT03741439

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham treatment
Study: NCT03426215

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: Changes in size and severity of the main herniated disc causing radiating pain will be evaluated by radiology specialists and Korean medicine doctors (KMDs) and categorized into three groups (improved, worse or no discernible change) in comparison with the immediate previous MRI to track long-term changes and assess for correlations in subjective clinical symptoms and objective physical evaluation and MRI results.
Study: NCT01864577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Negative Pleural Suction at -20 cm H2O

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water seal
Study: NCT04007874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol/levonorgestrel
Description: Ethinylestradiol/levonorgestrel 30/150 µg oral tablets once daily without a stopweek for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: Vitamin E 400 IU oral capsules once daily for 3 months
Study: NCT01310114

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Placenta-Derived Cells PDA001- (cenplacel-L)
Description: 240 mL of intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Placenta-Derived Cells PDA001- (cenplacel-L)
Description: 240 mL of intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Placenta-Derived Cells PDA001- (cenplacel-L)
Description: 240 mL of intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Thawed placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Thawed placebo
Study: NCT01864577

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water seal
Study: NCT03109951

Intervention type: DRUG
Group type: OTHER
Intervention: Colonoscopy preparation using polyethylene glycol
Description: Colonoscopy preparation using standard preparation with 2L of polyethylene glycol.
Study: NCT01496261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel and Aspirin
Description: Clopidogrel and Aspirin seperate combination, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose combination of clopidogrel/aspirin
Description: Fixed dose combination of clopidogrel/aspirin
Study: NCT01568229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 747
Description: Three dose levels once-daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 747
Description: Three dose levels once-daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 747
Description: Three dose levels once-daily oral administration
Study: NCT04135625

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated nutrition and agricultural (INA) trainings
Description: Monthly INA training session to help increase knowledge about nutrition and chicken husbandry and help to increase resiliency on a household level.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated nutrition and agricultural (INA) trainings
Description: Monthly INA training session to help increase knowledge about nutrition and chicken husbandry and help to increase resiliency on a household level.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ceremonial Gifting of Livestock
Description: Egg laying chickens will be presented as a gift to the child by a community champion (their religious leader or village chief)) during a gifting ceremony
Study: NCT01993355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physical therapy exercise program for CLBP patients. Its goal is to reduce pain and improve patients' health-related quality of life, functional capacity and well-being.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physical therapy exercise program for CLBP patients. Its goal is to reduce pain and improve patients' health-related quality of life, functional capacity and well-being.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Physical therapy exercise program for CLBP patients. Its goal is to reduce pain and improve patients' health-related quality of life, functional capacity and well-being.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention 1
Description: Relaxation techniques-sophrology consists of a set of physical and relaxation exercises that include breathing methods, visualization, modification of states of consciousness, etc. with the goal to enhance balance between body and mind to improve health-related quality of life, reduce pain and foster patients' well-being.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention 2
Description: Cognitive-behavioral therapy (in combination with motivational interviewing principles) is aimed to facilitate psychological adjustment and self-management of CLBP with the ultimate goal of increasing patients' health-related quality of life and well-being.
Study: NCT02163330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Study: NCT01568229

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily oral administration
Study: NCT01048515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine capsule 6 mg/kg given 1 hour before test

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine
Description: Caffeine capsule 6 mg/kg given 1 hour before test
Study: NCT01718314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Misoprostol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine pump spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Misoprostol)
Description: Lactose filler, the pharmacy-produced pills identical to original misoprostol pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Lidocaine)
Description: The pharmacy-produced sterile saline containing pump spray external characteristics identical to lidocaine pump spray
Study: NCT02858388

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sinuclean Nebules 45
Description: Nebulization of solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Nebulization of solution
Study: NCT04596657

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Description: Daily vitamin D3 supplementation (5000 IU)
Study: NCT00719810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: delafloxacin
Description: 300 mg intravenous every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: delafloxacin
Description: 450 mg intravenous every 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tigecycline
Description: 100 mg then 50 mg intravenous tigecycline every 12 hours
Study: NCT02536482

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amix
Description: Treat the children with cow's milk allergy for 5 months.
Study: NCT03517722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching to ustekinumab IV or SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab (approximately 6 mg/kg)
Description: Participants will receive ustekinumab approximately 6 mg/kg via IV route based on body weight-range.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Description: Participants will receive 90 mg ustekinumab via SC route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Description: Participants will receive 90 mg ustekinumab via SC route.
Study: NCT00450463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim (GM-CSF, Leukine)
Description: A recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) produced by recombinant deoxyribonucleic acid (DNA) technology in yeast Saccharomyces cerevisiae). Sargramostim is a 127 amino acid glycoprotein, altered from the native, natural human GM-CSF molecule; the position 23 arginine has been replaced with a leucine to facilitate the expression of the protein in yeast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide (Eulexin)
Description: Orally administered, nonsteroidal, competitive antagonist of testosterone and other androgens at androgenic receptors and may alter the nuclear translocation of the androgen/receptor complex.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flutamide (Eulexin)
Description: Orally administered, nonsteroidal, competitive antagonist of testosterone and other androgens at androgenic receptors and may alter the nuclear translocation of the androgen/receptor complex.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-F/ TRICOM
Description: A recombinant fowlpox virus vector vaccine containing the genes for human PSA and three costimulatory molecules.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-V/TRICOM
Description: A recombinant vaccinia virus vector vaccine containing the genes for human prostatic specific antigen (PSA) and three co-stimulatory molecules.
Study: NCT04715750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-PI2620
Description: \[18F\]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being evaluated for neurodegenerative decline. All patients will receive two administrations of \[18F\]PI-2620 at a radioactive dose of 185 MBq, one with high specific activity (≤ 5 µg tracer mass dose), another one with low specific activity (40-50 µg tracer mass dose).
Study: NCT02247206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Therapy for Tics (CBIT)
Description: CBIT is an 8-session 10-week behavioral treatment for chronic tic disorders, including Tourette Syndrome. The first two sessions are 90 minutes, with subsequent sessions lasting 60 minutes. The treatment consists of Habit Reversal Training (awareness training, competing response training, and social support), and function-based assessment to reduce the impact of environmental or other stimuli on tic severity. The treatment also consists of relaxation techniques to reduce tic-related stress and tension, and behavioral rewards to motivate treatment compliance.
Study: NCT04663035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg, iv. drip, Q3W. Tislelizumab will start within 3-7 days after ablation treatment. The longest course of treatment is 12 months.
Study: NCT03825562

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: acceptance and commitment therapy, ACT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: acceptance and commitment therapy, ACT
Study: NCT00673010

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 131 I-iodine (131-I), 124 I-iodine (124-I)
Description: Those who have demonstrated metastases which concentrate radioiodine will undergo routine testing to determine the MTA for blood and lung tissue. This will be performed with 124-I instead of 131-I. If the diagnostic scans (done with 123-I) show that the metastatic lesions concentrate radioiodine, the patient will be treated with 131-I based on standard of care discussions at a tumor board meeting. One week following the 131-I therapy, a whole body scan will be obtained and compared with the 124-I diagnostic scan. One year later, another extent of disease workup will be performed which will include 124-I dosimetry and scanning.
Study: NCT01548586

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eldith DC stimulator ( Magstim Company Ltd. UK)
Description: Anodal tDCS: Intensity of 2 mA , during 10 min Cathodal tDCS: Intensity of 2 mA , during 10 min Placebo type tDCS: Intensity of 0 mA during 10 min

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eldith DC stimulator ( Magstim Company Ltd. UK)
Description: Anodal tDCS: Intensity of 2 mA , during 10 min Cathodal tDCS: Intensity of 2 mA , during 10 min Placebo type tDCS: Intensity of 0 mA during 10 min

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Eldith DC stimulator ( Magstim Company Ltd. UK)
Description: Anodal tDCS: Intensity of 2 mA , during 10 min Cathodal tDCS: Intensity of 2 mA , during 10 min Placebo type tDCS: Intensity of 0 mA during 10 min
Study: NCT01885819

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous stromal vascular fraction cells
Study: NCT02224144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 1000 IU per day for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 1000 IU per day for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: Calcitriol (Rocaltrol) 0.5 mcg per day for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (sugar pill) 1 pill per day for 12 months
Study: NCT02014454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol eye drops
Description: All the enrolled preterm newborns will receive propranolol as ophthalmic solution (0,1%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, three times daily (every 8 hours).The treatment will continue until the complete development of retinal vascularisation, but no more than 60 days.~The propranolol treatment will be always associated to the conventional approach adopted by the ETROP Cooperative Group.
Study: NCT00392509

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ALDH-br bone marrow cells vs. mononuclear bone marrow cells
Description: Surgery
Study: NCT04197323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil liposomes for injection
Description: 40ug,once a day,continuous administration for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprostadil liposomes for injection
Description: 40ug,once a day,continuous administration for 2 weeks
Study: NCT01064622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study: NCT00013390

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tinnitus Masking
Description: Tinnitus Masking is a widely-used method for providing relief of tinnitus. The central premise of Tinnitus Masking involves the use of wearable ear-level devices (hearing aids, maskers, or combination instruments) that deliver sound to a patient's ear(s). The primary purpose of the sound presentation is to produce a sense of relief from the annoyance caused by the tinnitus sound. The relief is accomplished by either obscuring, or covering up (masking) the tinnitus sound, or by changing the sound of the tinnitus in some way, usually by reducing its loudness (Vernon, Meikle).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tinnitus Retraining Therapy
Description: Tinnitus Retraining Therapy (TRT) was derived from a purely psychological approach for facilitating tinnitus habituation (Hallam et al). The current method is based on neurophysiological principles, and aims at retraining brain regions that are involved in processing the tinnitus signal, without attempting to suppress generation of the signal (Jastreboff). The retraining involves a systematic effort aimed at decreasing both the detectability of tinnitus and the transmission of the tinnitus signal to emotional centers of the brain. Habituation of tinnitus thus purportedly occurs at two levels: habituation of emotional reactions to the tinnitus and habituation of tinnitus perception. Habituation is achieved by utilizing directive counseling, along with the use of low-level broadband noise to reduce the detectability of tinnitus for patients with normal or near-normal hearing. When hearing loss is a significant problem to the patient, appropriate hearing aids are fitted.
Study: NCT01064622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone/Placebo
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study: NCT02363764

Intervention type: PROCEDURE
Intervention: Nasal swab
Description: Will be obtained by the physiotherapist in:~* Expectorating CF patients~* Non-expectorating CF patients~* Bronchoscopy CF patients

Intervention type: PROCEDURE
Intervention: Nasal swab
Description: Will be obtained by the physiotherapist in:~* Expectorating CF patients~* Non-expectorating CF patients~* Bronchoscopy CF patients

Intervention type: PROCEDURE
Intervention: Nasal swab
Description: Will be obtained by the physiotherapist in:~* Expectorating CF patients~* Non-expectorating CF patients~* Bronchoscopy CF patients

Intervention type: PROCEDURE
Intervention: Cough swab
Description: Will be obtained by the physiotherapist in:~* Expectorating CF patients~* Non-expectorating CF patients~* Bronchoscopy CF patients

Intervention type: PROCEDURE
Intervention: Cough swab
Description: Will be obtained by the physiotherapist in:~* Expectorating CF patients~* Non-expectorating CF patients~* Bronchoscopy CF patients

Intervention type: PROCEDURE
Intervention: Cough swab
Description: Will be obtained by the physiotherapist in:~* Expectorating CF patients~* Non-expectorating CF patients~* Bronchoscopy CF patients

Intervention type: PROCEDURE
Intervention: Spontaneous expectorated sputum
Description: Will be obtained by the physiotherapist in:~- Expectorating CF patients

Intervention type: PROCEDURE
Intervention: Induced sputum
Description: Will be obtained by the physiotherapist in:~* Non-expectorating CF patients~* Bronchoscopy CF patients

Intervention type: PROCEDURE
Intervention: Induced sputum
Description: Will be obtained by the physiotherapist in:~* Non-expectorating CF patients~* Bronchoscopy CF patients

Intervention type: PROCEDURE
Intervention: Bronchoalveolar lavage
Description: Will be obtained by the pulmonologist in:~- Bronchoscopy CF patients

Intervention type: OTHER
Intervention: Questionnaire
Description: Completing questionnaire on acceptability of different sampling methods by patients \>6 years of age

Intervention type: OTHER
Intervention: Questionnaire
Description: Completing questionnaire on acceptability of different sampling methods by patients \>6 years of age
Study: NCT00533507

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix
Description: Intramuscular injection, 3 doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: Oral, 2 doses.
Study: NCT01426555

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FES-Rowing
Description: FES- Rowing Exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FES-Rowing
Description: FES- Rowing Exercise

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: 5 mg IV single dose
Study: NCT03878069

Intervention type: BIOLOGICAL
Intervention: elapegademase-lvlr
Description: Revcovi is administered intramuscularly (i.m.). Weekly dosage is calculated in mg/kg of body weight, and can be adjusted over the course of the trial based on ADA activity and dAXP concentration as well as on clinical assessment by the treating physician.
Study: NCT04167436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: A minimum of four weeks of prehabilitation with exercise three times a week, protein and vitamin supplements, dietitian consultation and medical optimization prior to surgery.
Study: NCT01923389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg PF-05231023
Description: 100 mg IV infusion twice a week for 4 weeks
Study: NCT04932720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: chıld yoga programme
Description: Yoga sessions were in the form of 6 sessions and were held as 2 sessions per week. The program was given by an expert yoga instructor who has an international Yoga Alliance approved child and adolescent yoga certificate.Consisting of the components of Hatha Yoga (HY), one of the yoga types known and widely practiced all over the world; Sessions consisting of asanas (yoga postures), pranayamas (breathing techniques), relaxation, relaxation exercises and meditation were prepared. Sessions are 45 minutes; For those who are new to yoga for the first 15 minutes; mental and physical preparation; asanas, pranayamas were taught, drama followed by breathing exercises and asanas in the next 30 minutes, relaxation techniques (imaginary journey) and meditation in the last 15 minutes.